GSK, Telethon and OSR gene treatment for ADA-SCID approved

GlaxoSmithKline (GSK), Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) recently announced that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). For more information please see:

http://www.gsk.com/en-gb/media/press-releases/2016/strimvelistm-receives-european-marketing-authorisation-to-treat-very-rare-disease-ada-scid/